Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rated to Overweight with price target $38 by Barclays Capital
Barclays Capital rated Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX) to Overweight with price target $38.
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)
has assembled a world-class, award-winning team of analysts covering, credit, commodities, economics, emerging markets, equities, fixed income, foreign exchange and market strategy.
We provide in-depth analysis of companies and macro coverage across asset classes, markets and the world’s economies. We have a highly quantitative approach and our research is underpinned by sophisticated analytics. Combined, these provide clients with the tools and insights necessary for successful risk management and financing.
Our research teams are based in many of the world’s major financial centres providing our clients with a globally integrated perspective across products and geographies.